1.84
+0.06(+3.37%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.78 |
| Day High | 1.9 |
| Day Low | 1.78 |
| 52-Week High | 3.65 |
| 52-Week Low | 1.09 |
| Volume | 676,579 |
| Average Volume | 1.61M |
| Market Cap | 130.97M |
| PE | -1.1 |
| EPS | -1.67 |
| Moving Average 50 Days | 2.18 |
| Moving Average 200 Days | 2.14 |
| Change | 0.06 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $72.19 as of February 11, 2026 at a share price of $1.84. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 5 years ago, it would be worth $40.4 as of February 11, 2026 at a share price of $1.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will p
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
GlobeNewswire Inc.
Jan 14, 2026 12:00 PM GMT
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will partici